Due to the pandemic, clinical trials evolved to replace traditional processes and address prevailing trial efficiencies. The growth of CROs has been influenced by the cost of R&D, tech and digitalization of clinical trials, the increase in advanced therapies and personalized medicine. In 2020, a 95% decline in CVD trial activity was estimated. Two years later, CVD has been identified as one of the most rapidly growing therapeutic areas in clinical trials.

This white paper will cover:

• Growth in demand for cardiology CRO Services
• Growth in the Cardiovascular Drugs Market
• Cardiovascular Clinical Trial Market in the U.S.
• Conduct of Clinical Trials in the Era of COVID-19